ClinicalTrials.gg
CompletedNCT03987919SURPASS-2Updated Feb 14, 2022Results posted

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

A Phase 3 interventional study of Tirzepatide and Semaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 127 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,879
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
3rd of 43
1,879 · median 160
Started
2019
with 7 others
Phase 3
17 of 43
1 open now
Registered
11th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • T2DM
  • GLP-1 RA
  • Glucose-dependent insulinotropic polypeptide (GIP)
  • glucagon-like peptide-1 (GLP-1)
  • GIP/GLP-1 dual receptor agonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with type 2 diabetes mellitus (T2DM)
  • Have between ≥7.0% and ≤10.5%
  • Be on stable treatment with unchanged dose of metformin >1500 mg/day for at least 3 months prior to screening
  • Be of stable weight (±5%) for at least 3 months before screening
  • Have a (BMI) ≥25 kilograms per meter squared (kg/m²) at screening

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have had chronic or acute pancreatitis any time prior to study entry
  • Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment
  • Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood (ALT) enzyme level >3.0 times the (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range
  • Have an estimated \<45 milliliters/minute/1.73 m² (or lower than the country specific threshold for using the protocol required dose of metformin per local label)
  • Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
  • Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
  • Have been taking any other diabetes medicines other than metformin during the last 3 months
  • Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,879 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    10 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    15 mg tirzepatide administered SC once a week.

    Drug: Tirzepatide

  • Active comparator
    1 mg Semaglutide

    1 mg semaglutide administered SC once a week.

    Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Change From Baseline in HbA1c (5 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  2. Change From Baseline in Body Weight

    Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  3. Percentage of Participants Achieving an HbA1c Target Value of <7%

    Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Week 40

  4. Change From Baseline in Fasting Serum Glucose (FSG)

    Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  5. Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  6. Percentage of Participants Who Achieved Weight Loss ≥5%

    Percentage of Participants who Achieved Weight Loss ≥5%.

    Time frame: Week 40

  7. Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Total Score

    DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS Mean was determined by ANCOVA with Baseline DTSQs + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 40

  8. Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia

    The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment.

    Time frame: Baseline through Safety Follow-Up (Up to Week 44)

  9. Percentage of Participants Achieving an HbA1c Target Value of <5.7%

    Percentage of Participants Achieving an HbA1c Target Value of \<5.7%.

    Time frame: Week 40

07

Results

Posted Feb 14, 2022

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Started471469470469
Received at least one dose of study drug470469470469
Completed452442446443
Not completed19272426
Withdrew: Adverse event1413
Withdrew: Death4441
Withdrew: Lost to follow-up56812
Withdrew: Physician decision0204
Withdrew: Pregnancy1011
Withdrew: Protocol violation0100
Withdrew: Site terminated by sponsor0001
Withdrew: Withdrawal by subject7784
Withdrew: Other - as reported by the investigator1320

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Percentage of HbA1c10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)-2.37 ± 0.048-2.46 ± 0.048-1.86 ± 0.048
Statistical analysis
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.51 · 95% CI -0.64 to -0.38
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.60 · 95% CI -0.73 to -0.47
SecondaryChange From Baseline in HbA1c (5 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c (5 mg)
Percentage of HbA1c5 mg Tirzepatide1 mg Semaglutide
Change From Baseline in HbA1c (5 mg)-2.09 ± 0.047-1.86 ± 0.048
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.23 · 95% CI -0.36 to -0.10
SecondaryChange From Baseline in Body Weight

Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Kilograms (kg)
Change From Baseline in Body Weight
Kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Change From Baseline in Body Weight-7.8 ± 0.33-10.3 ± 0.34-12.4 ± 0.34-6.2 ± 0.33
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.7 · 95% CI -2.6 to -0.7
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.1 · 95% CI -5.0 to -3.2
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.2 · 95% CI -7.1 to -5.3
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <7%

Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an HbA1c Target Value of <7%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Percentage of Participants Achieving an HbA1c Target Value of <7%85.4788.8992.2481.13
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = 0.023 · Odds ratio (or): 1.54 · 95% CI 1.06 to 2.23
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.14 · 95% CI 1.44 to 3.17
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.03 · 95% CI 1.97 to 4.66
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligram per Deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per Deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Change From Baseline in Fasting Serum Glucose (FSG)-56.0 ± 1.57-61.6 ± 1.60-63.4 ± 1.59-48.6 ± 1.58
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = 0.001 · Ls mean difference: -7.3 · 95% CI -11.7 to -3.0
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.0 · 95% CI -17.4 to -8.6
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Mixed Models Analysis · p = <0.001 · Ls mean difference: -14.7 · 95% CI -19.1 to -10.3
SecondaryMean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values

The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · mg/dL
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values
mg/dL5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Mean Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) Values-65.4 ± 1.04-70.6 ± 1.05-74.3 ± 1.05-61.4 ± 1.04
SecondaryPercentage of Participants Who Achieved Weight Loss ≥5%

Percentage of Participants who Achieved Weight Loss ≥5%.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Percentage of Participants Who Achieved Weight Loss ≥5%68.5582.3586.2158.44
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = 0.001 · Odds ratio (or): 1.58 · 95% CI 1.20 to 2.08
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.49 · 95% CI 2.57 to 4.75
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.60 · 95% CI 3.32 to 6.38
SecondaryDiabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Total Score

DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS Mean was determined by ANCOVA with Baseline DTSQs + Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Units on a Scale
Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Total Score
Units on a Scale5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Hyperglycemia-1.3 ± 0.10-1.4 ± 0.10-1.5 ± 0.10-1.1 ± 0.10
Hypoglycemia-0.7 ± 0.10-0.7 ± 0.10-0.8 ± 0.10-0.7 ± 0.10
Total Score15.7 ± 0.1815.6 ± 0.1916.1 ± 0.1915.8 ± 0.19
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.084 · Ls mean difference: -0.24 · 95% CI -0.50 to 0.03
  • 10 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.050 · Ls mean difference: -0.27 · 95% CI -0.54 to 0.00
  • 15 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.005 · Ls mean difference: -0.39 · 95% CI -0.66 to -0.12
  • 5 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.688 · Ls mean difference: -0.06 · 95% CI -0.33 to 0.22
  • 10 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.909 · Ls mean difference: -0.02 · 95% CI -0.29 to 0.26
  • 15 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.358 · Ls mean difference: -0.13 · 95% CI -0.40 to 0.15
  • 5 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.701 · Ls mean difference: -0.10 · 95% CI -0.62 to 0.41
  • 10 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.341 · Ls mean difference: -0.25 · 95% CI -0.78 to 0.27
  • 15 mg Tirzepatide vs 1 mg Semaglutide · ANCOVA · p = 0.321 · Ls mean difference: 0.26 · 95% CI -0.26 to 0.79
SecondaryRate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia

The hypoglycemia events were defined by participant reported events with blood glucose \<54mg/dL) (\<3.0 mmol/L\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Treatment.

Time frame:
Baseline through Safety Follow-Up (Up to Week 44)
Reported as:
Mean · Episodes/participant/365.25 days
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia
Episodes/participant/365.25 days5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Rate of Hypoglycemia With Blood Glucose <54 Milligram/Deciliter (mg/dL) [<3.0 Millimole/Liter (mmol/L)] or Severe Hypoglycemia0.0102 ± 0.004230.0046 ± 0.004880.0202 ± 0.008400.0046 ± 0.00340
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <5.7%

Percentage of Participants Achieving an HbA1c Target Value of \<5.7%.

Time frame:
Week 40
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an HbA1c Target Value of <5.7%
Percentage of Participants5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Percentage of Participants Achieving an HbA1c Target Value of <5.7%29.2844.6650.8619.74
Statistical analysis
  • 5 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 1.86 · 95% CI 1.35 to 2.57
  • 10 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.94 · 95% CI 2.88 to 5.39
  • 15 mg Tirzepatide vs 1 mg Semaglutide · Regression, Logistic · p = <0.001 · Odds ratio (or): 5.10 · 95% CI 3.73 to 6.97

Adverse events

Collected over Baseline, Safety follow-up (44 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide4/470 (0.9%)33/470 (7%)170/470 (36.2%)
10 mg Tirzepatide4/469 (0.9%)25/469 (5.3%)187/469 (39.9%)
15 mg Tirzepatide4/470 (0.9%)27/470 (5.7%)202/470 (43%)
1 mg Semaglutide1/469 (0.2%)13/469 (2.8%)172/469 (36.7%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
Covid-19 pneumoniaInfections and infestations2/4702/4692/4704/469
EpididymitisInfections and infestations1/2050/2380/2140/225
Cholecystitis acuteHepatobiliary disorders1/4702/4692/4700/469
Urinary tract infectionInfections and infestations0/4702/4690/4700/469
Acute myocardial infarctionCardiac disorders2/4700/4692/4700/469
Atrial fibrillationCardiac disorders2/4700/4690/4700/469
Cerebrovascular accidentNervous system disorders0/4700/4692/4700/469
Uterine prolapseReproductive system and breast disorders0/2650/2310/2561/244
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2650/2311/2560/244
Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2650/2310/2560/244
Most frequent other events
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg Semaglutide
NauseaGastrointestinal disorders82/47090/469104/47084/469
DiarrhoeaGastrointestinal disorders62/47077/46965/47054/469
VomitingGastrointestinal disorders27/47039/46946/47039/469
DyspepsiaGastrointestinal disorders34/47029/46943/47031/469
Decreased appetiteMetabolism and nutrition disorders35/47034/46942/47025/469
ConstipationGastrointestinal disorders31/47021/46921/47027/469
Abdominal painGastrointestinal disorders14/47020/46924/47024/469

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
Mean56.3 ± 10.057.2 ± 10.555.9 ± 10.456.9 ± 10.856.6 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
Female265231256244996
Male205238214225882
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
Hispanic or Latino3253223343361317
Not Hispanic or Latino145147136133561
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
American Indian or Alaska Native53535745208
Asian6115325
Native Hawaiian or Other Pacific Islander00123
Black or African American2821151579
White3823763924011551
More than one race180312
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
Argentina158160161161640
Australia1211121146
Brazil37373637147
Canada1515141559
Israel2222222187
Mexico89878888352
Puerto Rico646319
United Kingdom1818181872
United States113115113115456
Hemoglobin A1c
Hemoglobin A1c(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg Tirzepatide1 mg SemaglutideTotal
Mean8.32 ± 1.088.30 ± 1.028.26 ± 1.008.25 ± 1.018.28 ± 1.03
08

Study locations

127 sites
  • Cahaba Research
    Birmingham, Alabama 35242, United States
  • Syed Research Consultants Llc
    Sheffield, Alabama 35660, United States
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • National Research Institute - Huntington Park
    Panorama City, California 91402, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • University Clinical Investigators, Inc.
    Tustin, California 92780, United States
  • CMR of Greater New Haven
    Hamden, Connecticut 06517, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • East Coast Institute for Research at The Jones Center
    Lake City, Florida 32055, United States
  • South Florida Clinical Research Institute
    Margate, Florida 33063, United States
  • Suncoast Research Group
    Miami, Florida 33135, United States
  • New Horizon Research Center
    Miami, Florida 33165 3338, United States
  • Oviedo Medical Research
    Oviedo, Florida 32765, United States
  • South Broward Research
    Pembroke Pines, Florida 33027, United States
  • United Osteoporosis Center
    Gainesville, Georgia 30501, United States
  • Sky Clinical Research Network
    Union City, Georgia 30291, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • University of Iowa Hospital & Clinic
    Iowa City, Iowa 52242, United States
  • Cotton O'Neil Clinic
    Topeka, Kansas 66606, United States
  • Cotton O'Neil Diabetes and Endocrinology Center
    Topeka, Kansas 66606, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Premier Research
    Trenton, New Jersey 08611, United States
  • Albany Medical College, Division of Community Endocrinology
    Albany, New York 12206, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • Diabetes & Endocrinology Consultants, PC
    Morehead City, North Carolina 28557, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Intend Research, LLC
    Norman, Oklahoma 73069, United States
  • Heritage Valley Medical Group, Inc.
    Beaver, Pennsylvania 15009, United States
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania 17011, United States
  • Detweiler Family Medicine & Associates
    Lansdale, Pennsylvania 19446, United States
  • Green & Seidner Family Practice Associates
    Lansdale, Pennsylvania 19446, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
    Pittsburgh, Pennsylvania 15243, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Biopharma Informatic, Inc.
    Houston, Texas 77043, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Carl R. Meisner Medical Clinic, PLLC
    Sugar Land, Texas 77478, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • Burke Internal Medicine and Research
    Burke, Virginia 22015, United States
  • Capital Clinical Research Center
    Olympia, Washington 98502, United States
  • The Vancouver Clinic
    Vancouver, Washington 98664, United States
  • CEDIC
    Caba, Ar-b C1425DES, Argentina
  • CIPREC
    Ciudad Autonoma de Buenos Aire, Ar-b C1119ACN, Argentina
  • Investigaciones Medicas Imoba Srl
    Buenos Aires, Ar-c C1179AAB, Argentina
  • CEMEDIAB
    C.a.b.a., Ar-c C1205AAO, Argentina
  • Sanatorio Norte
    Santiago del Estero, Ar-g 4200, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Caba, Buenos Aires C1056ABJ, Argentina
  • Centro Médico Viamonte
    Caba, Buenos Aires C1120AAC, Argentina
  • Centro Medico Dr Laura Maffei Investigacion Clinica Aplicada
    Caba, Buenos Aires C1425AGC, Argentina
  • Mautalen Salud e Investigacion-Centro de Osteopatías Médicas
    Ciudad Autonoma De Buenos Air, Buenos Aires C1128AAF, Argentina
  • CIPADI
    Godoy Cruz, Mendoza M5501ARP, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Provincia De Buenos Aires (B7600FZN), Argentina
  • Instituto Centenario
    Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
  • Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC
    Cordoba, X5008HHW, Argentina
  • Paratus Clinical Research Western Sydney
    Blacktown, Au-nsw 2148, Australia
  • Campbelltown Medical & Dental Centre
    Campbelltown, Au-nsw 2560, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, Au-nsw 2259, Australia
  • Holdsworth House Medical Practice
    Sydney, New South Wales 2010, Australia
  • GenesisCare - Bundaberg
    Bundaberg, Queensland 4670, Australia
  • Royal Brisbane and Womens Hospital
    Herston, Queensland 4029, Australia
  • Core Research Group
    Milton, Queensland 4064, Australia
  • AusTrials
    Taringa, Queensland 4068, Australia
  • Eastern Clinical Research Unit
    Box Hill, Victoria 3128, Australia
  • Barwon Health - The Geelong Hospital
    Geelong, Victoria 3220, Australia
  • GenesisCare - Wexford Medical Centre WA
    Joondalup, Western Australia 6027, Australia
  • GenesisCare - Wexford Medical Centre WA
    Murdoch, Western Australia 6150, Australia
  • Adelaide Medical Solutions
    Woodville South, 5011, Australia
  • CEDOES
    Vitória, Br-es 29055450, Brazil
  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas
    São José dos Campos, Br-sp 12243-280, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, Br-sp 01228-000, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, Br-sp 04266-010, Brazil
  • Centro de Pesquisas em Diabetes
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • CPCLIN
    São Paulo, SP 01228-200, Brazil
  • Dr. Consulta Clínica Médica LTDA
    São Paulo, 05016-090, Brazil
  • Milestone Research Inc.
    London, Ca-on N5W 6A2, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ca-on N7T 4X3, Canada
  • Dr. Anil K. Gupta Medicine Professional Corporation
    Toronto, Ca-on M9V 4B4, Canada
  • Manna Research
    Lévis, Ca-qc G6W 0M5, Canada
  • Manna Research - Burlington North
    Burlington, Ontario L7M 4Y1, Canada
  • Manna Research - Burlington North
    Nepean, Ontario K2J 4A7, Canada
  • Manna Research - Burlington North
    Stoney Creek, Ontario L8J 3W2, Canada
  • Manna Research - Burlington North
    Toronto, Ontario M9W 4L6, Canada
  • Meir Medical Center
    Kfar Saba, HaMerkaz 4428164, Israel
  • Clalit Health Services - Shuali Clinic
    Raanana, HaMerkaz 43405, Israel
  • Sheba Medical Center
    Ramat Gan, HaMerkaz 5262100, Israel
  • Diabetes Medical Center
    Tel Aviv, Il-ta 51549, Israel
  • Hadassah Medical Center
    Jerusalem, Yerushalayim 9112001, Israel
  • Clalit Health Services - Sakhnin Community Clinic
    Sakhnin, 3081000, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv Jaffa, 6423906, Israel
  • Rambam Health Care Campus
    Haifa, Ḥeifā 3109601, Israel

Showing the first 100 of 127 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ten Doesschate T, van der Vaart TW, Debisarun PA, Taks E, Moorlag SJCFM, Paternotte N, Boersma WG, Kuiper VP, Roukens AHE, Rijnders BJA, Voss A, Veerman KM, Kerckhoffs APM, Oever JT, van Crevel R, van Nieuwkoop C, Lalmohamed A, van de Wijgert JHHM, Netea MG, Bonten MJM, van Werkhoven CH. Bacillus Calmette-Guerin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial. Clin Microbiol Infect. 2022 Sep;28(9):1278-1285. doi: 10.1016/j.cmi.2022.04.009. Epub 2022 Apr 28. PubMed 35489606 ↗
  • Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598. doi: 10.1038/s41591-022-01707-4. Epub 2022 Feb 24. PubMed 35210595 ↗
  • Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PubMed 34170647 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2021, 17 months.

Results were first posted in Feb 2022, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 17 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jun 17, 2019
StartActual
Jul 30, 2019
Primary completionActual
Jan 28, 2021
CompletionActual
Feb 15, 2021
Results first posted
Feb 14, 2022
Last update
Feb 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03987919
Responsible party
Sponsor
First posted
Jun 17, 2019
Start date
Jul 30, 2019
Primary completion
Jan 28, 2021
Completion
Feb 15, 2021
Results posted
Feb 14, 2022
Last update
Feb 14, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion